Dr. Marta Ann Crispens, MD

Dr. Crispens practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Crispens' NPI, 1578650685, was assigned on October 9, 2006. Dr. Crispens graduated from University of Alabama School of Medicine in 1991. Dr. Crispens holds Tennessee license MD36626.

Dr. Crispens' primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Dr. Crispens' primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. Dr. Crispens is also affiliated with Vanderbilt Wilson County Hospital. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Crispens to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crispens practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Crispens' primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Crispens is licensed in Tennessee.

CMS data shows 234 Medicare services from Dr. Crispens across 5 procedure codes in 2024, for 122 Medicare patients. Medicare paid $14,147 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 122 Medicare patients who saw Dr. Crispens in 2024. The largest group is 65 to 74, with 77 patients. 75% of them have high blood pressure, and 67% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Crispens' median patient age at 67, with 99% women.

In 2024, Dr. Crispens wrote 291 Medicare Part D claims for 55 patients. 86% of them were for generic drugs. CMS names the drug for 167 of them, across 9 drugs with 11 or more claims each, at $212,707 in total drug cost. In 2023, CMS named 206 claims across 7 drugs.

Dr. Crispens accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Crispens as offering telehealth.

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 47 papers to Dr. Crispens, published from 2011 to 2025. 2020 was the busiest year, with 5. The most frequent topics are Ovarian Neoplasms, Immunohistochemistry and Biomarkers, Tumor. Dr. Crispens has published most often in J Natl Compr Canc Netw. Dr. Crispens' most frequent co-authors are Dineo Khabele, MD, Oluwole O. Fadare, MD and David K. Gaffney, MD, PhD.

Dmand AI links Dr. Crispens to 8 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 13 general payments to Dr. Crispens from 4 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 87% of the total. AstraZeneca Pharmaceuticals LP paid the most, $6,398.

Dr. Crispens graduated from University of Alabama School of Medicine in 1991.